The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly meet tomorrow, January 14, to review and discuss Nektar Therapeutics’ (NKTR +1.2%) marketing application seeking approval to use opioid oxycodegol (NKTR-181) to treat adults with chronic low back pain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.